Cancer remains one of the most challenging conditions to study and treat. Oncology drug trials are faced with extreme costs, long durations, and high failure rates, which often leaves patients with few treatment options, exorbitantly high costs of care, and a devastating prognosis.
Wearable sensors and connected digital technologies have the potential to revolutionize how we study, treat, and manage cancer research and care. Their ease of use and passive, low burden nature allow for the continuous collection of important physiological and behavioral signals over prolonged periods of time. These real-world data provide an opportunity for oncology researchers to develop a new class of objective and sensitive endpoints that are clinically meaningful to this patient population and better reflect how they live and function outside of the clinic.
Despite these possibilities, the oncology community has been hesitant to embrace digital clinical measures. In fact, of the 207 (and counting) digital endpoints registered in the Digital Medicine Society’s (DiMe) crowd-sourced library of digital endpoints, none are being used in oncology.
Register for this webinar to hear from thought leaders in the field who are bucking this trend and making strides to integrate digital clinical measures in patient care and clinical research. Speakers will discuss how they are successfully deploying wearable and remote monitoring technologies to improve clinical outcomes in patients living with cancer. We will also discuss the reasons behind, and the missed opportunities from, the slow adoption of such tools. The webinar will conclude with a discussion of the high priority items needed to help digital clinical measures realize their potential in cancer research and care.
Jeremy Wyatt, Chief Executive Officer, ActiGraph
Jeremy Wyatt is the CEO of ActiGraph, a leading global provider of physical activity and sleep monitoring solutions for pharmaceutical and academic industries. With two decades of embedded hardware systems development and related cloud technology expertise, Jeremy has a uniquely well-rounded perspective on the challenges and opportunities of deploying wearable technologies to capture accurate and meaningful patient data.
He is considered an industry thought leader and expert in the clinical biosensor space and is a frequent representative and contributor at clinical drug development commercial events, scientific consortiums and FDA/EMA regulatory meetings. He has an undergraduate degree in electrical engineering from the University of Florida and an MBA from the University of West Florida. Jeremy is a member and contributor to the Digital Medicine (DiMe) Society and participates in various digital biomarker efforts with the Clinical Trial Transformation Initiative (CTTI).
Kate Lyden, PhD, Chief Science Officer, VivoSense
Kate Lyden, PhD is the Chief Science Officer for VivoSense, an agile end-to-end solutions company measuring patient outcomes by developing novel digital endpoints from wearable sensor data. Kate has an extensive and diverse background in the development and implementation of wearable sensor methodologies across clinical, academic, and industry settings. She is passionate about leveraging the power of connected sensor technologies to gain meaningful insights into real-world patient behaviors and experiences. Prior to joining VivoSense, Kate spent nearly ten years as an academic researcher focused on synchronizing continuous measures of real-world behavior with physiological signals to reveal associations between important health behaviors and risk for chronic disease. She has authored many scientific publications on the objective measurement of human behaviors and is a frequent contributor and collaborator on this topic at clinical development commercial events and industry working groups.
Ariel Aguiló, MD, Executive Medical Director, Head of the Americas Oncology Medical Team, Labcorp Drug Development
Ariel Aguiló, MD, is a board-certified oncologist specialized in gastrointestinal tumors. He is an Executive Medical Director and Head of the Americas Oncology Medical Team for Labcorp Drug Development, based in Buenos Aires, Argentina. He brings more than 10 years of experience as a physician and vast experience leading global trials. He also provides subject matter expertise and support for the development and conduct of clinical trials on client’s drug development projects.
Jorge Nieva, Associate Professor of Clinical Medicine, Keck School of Medicine of USC
Dr. Jorge Nieva is the section head of solid tumors, division of medical oncology at the Keck School of Medicine and director of the lung cancer research program within the USC/Norris Cancer Center. He serves as the chair of the data and safety monitoring committee at the cancer center and leads the internal advisory committee for the CARE2 Health Equity Center at USC. Dr. Nieva is an expert in biomarker development and informatic approaches to the evaluation of patient health. He is a graduate of the University of California Irvine College of Medicine, trained internal medicine at the University of California, San Diego and in Oncology/Hematology at the Scripps Clinic. Prior to joining the faculty at USC, he was on the faculty at the Scripps Research Institute and the Billings Clinic.
Heather Jim, Ph.D. Senior Member and Co-Leader, Health Outcomes and Behavior Program, Moffitt Cancer Center
Heather Jim Ph.D. is a Senior Member and Co-Leader of the Health Outcomes and Behavior Program at Moffitt Cancer Center. Her research focuses on the psychological and physical effects of cancer diagnosis and treatment. She has four lines of research dedicated to: 1) documenting the prevalence, severity, and chronicity of side effects of cancer and its treatment, 2) determining which patients are at the greatest risk of developing side effects, 3) understanding underlying biological and behavioral mechanisms, and 4) developing and evaluating targeted interventions to prevent or reduce side effects. She has published extensively on these topics and has an active program of federally-funded research.
Who Should Attend?
- Chief Development Officers/Managers
- Chief Medical Officers
- Clinical Operations and Operational Directors/Managers
- Data Managers
- Innovations Managers
- Regulatory Directors/Managers
- Procurement Directors/Managers
- Technology Leaders and Experts
What You Will Learn
In this webinar participants will learn:
- The unique barriers to applying wearable sensors and connected digital technologies in oncology research and care
- How digital technologies can overcome current barriers to make meaningful improvements in oncology research and care
ActiGraph’s mission is to bring life to digital data. Built on more than twenty years of remote data capture expertise, ActiGraph is the leading provider of medical-grade wearable motion sensors for the global scientific community. ActiGraph’s FDA-cleared biosensors and flexible technology ecosystem deliver high quality, continuous digital data, providing valuable insights into the real-world behaviors of clinical trial participants. Appearing in more than 17,000 published scientific papers to date, ActiGraph is the industry’s most experienced, knowledgeable.
VivoSense is an agile end to end solutions company measuring patient outcomes by developing novel digital endpoints from wearable sensor data focused on healthcare research & delivery, clinical trials and patient wellness.